10 to 15 % of people are concerned by metabolic, traumatic or aged dependent osteoarthritis with a prevalence of 10 % per year.
No cure is currently available and only symptomatic treatments are reimbursed by health insurances.
A strong protective effect against metabolic osteoarthritis was obtained by a molecule with a marketing authorization on another indication. This was shown on 100 % of rats exhibiting metabolic syndrome that all develop metabolic osteoarthritis.
These early results will undergo preclinical proof of concept studies for efficacy in the next months on rats with early metabolic osteoarthritis and/or early traumatic osteoarthritis.
MARKETS AND APPLICATIONS
TRL 4: in vivo protective results on rats
Proof of curative effect on rats are to come shortly
Published on February 1st, 2018
+33 (0)6 17 06 68 07